Incumplimiento y responsabilidad frente a terceros en el derecho francés : ¿cómo salir del punto muerto?

El artículo no presenta resumen

Procurement of Covid-19 vaccines: why were legal liabilities transferred to the public sector?

he recent release of the Covid-19 vaccine supply contract between the European Commission and Astra Zeneca has caused a political and media storm about vaccine production logistics and supply issues. A lesser noticed but controversial issue revealed by the contract is that of where ultimate liabilities should lie, which has potentially far-reaching consequences for the public purse. Many commercial contracts include so-called indemnity clauses hereby one party contractually agrees to cover liabilities incurred by the other. The European Commission accepted in Article 14 of the agreement an extremely broad indemnity of the manufacturer covering almost any and every defect imaginable whether that be the vaccine’s inherent characteristics, manufacturing / distribution, and storage issues, labelling errors or even problems due to administration of the vaccine. This is a potentially significant burden to place on the state, and ultimately taxpayers

COMPARING NO-FAULT COMPENSATION SYSTEMS FOR VACCINE INJURY

The policy responses to redressing serious adverse reactions caused by vaccines are many and varied. Scholars have identified three broad options for responding to the need for support of those who have been subject to vaccine injury. The first is a minimalist approach that entails injured persons bearing the costs associated with their injuries with assistance provided solely by means of standard social welfare and health benefits provided by the state. Second, compensation may be sought through legal proceedings brought against those responsible for producing, or in certain cases distributing, the vaccines in question. Third, compensation may be sought from a dedicated compensation scheme outside the normal litigation system, generally premised upon no-fault liability. The discussion in this Article focuses on the latter schemes, which are generally government-created and specifically respond to vaccine injuries. The advantages of such a mechanism over the other options, which entail either patients bearing the costs themselves or seeking compensation though litigation against private sector, have been widely discussed, and we will also examine the broader rationales below

Fait des produits : 1 - Fait des choses : 0

International audienc

La responsabilité du fait des produits de santé et l'étendue de l'harmonisation réalisée par la directive du 25 juillet 1985

International audienc

Qui doit répondre du dommage causé par un produit défectueux à des biens à usage professionnel ?

International audienceNon renseign

La responsabilité des contractants à l'égard des tiers dans le projet de réforme de la responsabilité civile

International audienc

Le dommage réparable en matière de responsabilité du fait des produits défectueux

International audienc

Un pas de plus vers la réforme de la responsabilité civile : présentation du projet de réforme rendu public le 13 mars 2017

International audienceNon renseign